Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

New Studies Confirm Benefits of CRS-HIPEC

As mesothelioma researchers and physicians continue to work towards improving treatment protocols for malignant peritoneal mesothelioma, information is being released showing various methodologies that are improving outcomes. Three separate international studies have just been published in support of the procedure known as Heated Intraperitoneal Chemotherapy, or HIPEC, in which heated chemotherapy drugs are administered directly into the surgical site following surgery to remove mesothelioma tumors. The drugs are then used as a post-operative rinse in order to remove as many remaining cancer cells as possible in order to stop or delay the return of the tumor.

The HIPEC treatment is relatively new and is not available at all cancer centers, but it is becoming increasingly accepted. The three studies were each aimed at finding ways to improve upon what is already being done.

In Canada, researchers have followed the use of the procedure for eight years, using the chemotherapy drug oxaliplatin. Between 2004 and 2012, the University of Montreal performed the proedure on patients with both epithelial and multicystic peritoneal mesothelioma, administering the heated chemotherapeutic agent for a period of thirty minutes. They found that patients who had the procedure lived at least a year following the procedure, with 91 percent surviving for three years. The procedure was well tolerated, with no patients dying as a result. The research concluded that the protocol is a valid treatment.

An Italian study followed a slightly different protocol in which the chemotherapy drug used was cisplatin and it was administered for a period of 60 minutes. The treatment was followed in six mesothelioma patients and two lung cancer patients, and revealed a mean survival of 13.6 months, with no patient deaths or major complications resulting from the treatment.

The last of the three studies was conducted in Singapore, where several patients who had varying cancers of the peritoneal area were treated using a combination of cytoreductive surgery and heated chemotherapy. Though one patient suffered some complications, the others went through the procedure with no complications and all of the latter group lived for a minimum of one year following the treatment. This group of researchers also determined that the use of CRS/HIPEC offers good outcomes in which select patients can “achieve prolonged survival”.

Terri Oppenheimer

Terri Oppenheimer is an independent writer, editor and proofreader. She graduated from the College of William and Mary with a degree in English. Her dreams of a writing career were diverted by a need to pay her bills. She spent a few years providing copy for a major retailer, then landed a lucrative career in advertising sales. With college bills for all three of her kids paid, she left corporate America for a return to her original goal of writing. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of interest include health and fitness, medical research, and the law.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –
1-800-692-8608


Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –
1-800-692-8608

We are here to help you

support_staff

If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started